CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Association of Cardiovascular Disease With Respiratory Disease Dapagliflozin for treating chronic heart failure with reduced ejection fraction The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure AIM2-driven inflammasome activation in heart failure Exercise Intolerance in Patients With Heart Failure: JACC State-of-the-Art Review A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. The Role of the Pericardium in Heart Failure: Implications for Pathophysiology and Treatment Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced

Original ResearchDecember 11, 2018 Vol 138, Issue 24

JOURNAL:Circulation. Article Link

Heart Failure With Preserved Ejection Fraction in the Young

J Tromp , MR MacDonald, CSP Lam et al. Keywords: HFpEF; age; obesity

FULL TEXT PDF